Next Phase Newsletter

A transatlantic investor founded in 2001 is based in Utrecht, the Netherlands with an additional operation in Boston, United States. The firm has raised more than €1.5 million across 3 of their most recently closed funds. The firm is currently investing from its latest fund with over €600M in committed capital. The investment size ranges from €10 million up to €60 million per portfolio company over the lifetime of the investment. The firm is seeking to make 2-3 investments over the next 6-9 months, targeting companies based in the U.S. and Europe.

The firm is currently looking for new investment opportunities in Diagnostics, Medical Devices and Digital Health spaces. The firm is very opportunistic in terms of subsectors and indications. The firm invests in all areas of life sciences, including therapeutics, medical devices, diagnostics and digital health companies. In the past, the firm did not look at therapeutics, but is now actively investing in therapeutics companies as well. For diagnostics and medical devices, the firm is interested in companies with commercial-stage/revenue-generating products, but may also look opportunistically at earlier stage technologies. These may include 510K devices where the FDA clearance is very close and/or where reimbursement is the last hurdle and feel confident in the path to reimbursement. For digital health, the firm looks opportunistically at companies beyond the Series A stage. Historically, the firm was active in medical device companies developing orthotic and prosthetic devices, as well as peripheral vascular applications in cardiovascular diseases.

The firm focuses on investments in private companies and it will consider pre-revenue companies, depending on the opportunity. The firm prefers to invest in companies with experienced and committed management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Located in Zhengzhou, China, a venture capital firm was founded in 2018 and is the corporate venture arm of Autobio Diagnostics. Through the parent company, funding is dedicated towards early-stage life science companies from Seed to Series B. The initial size of investment is less than $50M USD and the firm aims to invest in 3-5 companies in the upcoming year. The firm is open to global opportunities.

The firm will primarily consider therapeutics and diagnostics and is open to medical devices and digital health. Within therapeutics, the firm is opportunistic and looks at technologies from Pre-clinical to Phase I. The firm has more often invested in cell and gene therapies due to interest in vaccines. Within diagnostics, all modalities from in-development to clinical phases will be considered. The firm has more often invested in in-vitro testing kits and point-of-care testing diagnostics. The firm is opportunistic in the medical devices (in-development to clinical phases) and digital health sectors. While open to all indications, the firm has a particular interest in cancer.

The firm acts as a strategic lead investor and values technology with high potential to go through the approval process.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly established venture capital firm based in the USA  just successfully closed the first round of their fund ($20M target), and made its first investment. The firm invests globally in medically related early-stage companies. Initial size of investment ranges from $250 – 500K. While the firm is focused on USA-based companies, the firm is open to considering companies across the globe.

The firm invests in medtech and digital health companies. While the founder has decades of experience as an oculofacial plastic surgeon, the firm is generally opportunistic and will consider any promising technologies that address unmet medical need. The firm has looked at AI companies, digital health/software companies implementable in medical practices, etc. In terms of stage of development, the firm is open to investing as early as pre-prototype, given that the company has properly researched the idea behind their technology.

The firm has no specific company or management team requirements, and is open to acting as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

With about a month left until RESI Boston June 2023 and a few days before partnering launch, LSN is very excited to announce the list of 50+ finalist companies who will be participating in the Innovator’s Pitch Challenge (IPC)!

The deadline was set earlier than our usual IPC application cycles, but the RESI team still received a record number of applications.

Over 50 companies representing therapeutics, medical devices, diagnostics, digital health, and R&D / life science tools across the globe will be delivering a live pitch followed by a Q&A session with a panel of investors and industry experts. In addition, the companies will be presenting a poster showcasing their technology in the exhibit hall. We were very impressed by all of the amazing technologies developed by the IPC finalist companies and we cannot wait to showcase them at the upcoming RESI!

Below are the participating companies. If you are interested in seeing these pitches and engaging in one-on-one partnering with over 1,000 attendees expected to attend, you can register here!

RESI Boston June 2023 IPC Finalists

By Caitlin Dolegowski, Marketing Manager, LSN

RESI Boston, June 5-7 is rapidly approaching, and the partnering platform opens next Monday, May 15. This hybrid conference enables attendees to book meetings either in person on Monday, June 5, or virtually, June 6-7.  The LSN Partnering Platform offers startups the opportunity to search for and identify investors that are a fit for them based on sector, indication, stage of development and other criteria. Successful partnering takes a lot of work, and the companies that book the most meetings send, on average, over 100 meeting requests to relevant investors, followed by frequent follow-ups. We will be offering a free partnering tutorial next week to provide you with helpful insight into making the most of your time at RESI.

There is still time to register for RESI Boston, June 5-7 and meet with 350+ active investors in the life science industry.

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

RESI Boston during BIO week is just a few weeks away. We’ve already told you about the opportunity to meet with 350+ investors and licensing partners and amazing panels and workshops, but you will also be able to meet with some top service providers who may have just the product or service your company needs or will need in the future. RESI is the conference for early-stage partnering, where you can make connections that are focused on this space that you won’t find at other conferences that are geared toward later stage activities.

Here are some of the companies you can meet in the RESI Exhibition Hall this June.

See you in Boston! REGISTER HERE

By Momo Yamamoto, Investor Research Analyst, LSN

Time is flying by, and there is only a month left until RESI Boston! As a refresher, RESI Boston will be a 3-day hybrid conference, taking place on June 5^th – 7^th. June 5^th will be in-person at the Westin Copley Place, featuring Innovator’s Pitch Challenge (IPC) sessions, 7 investor panels, and educational workshops followed by all-day virtual partnering on June 6^th – 7^th.

Life Science Nation is excited to announce the 20+ panelists who have been selected to speak on our investor panels at RESI Boston. Panel topics include: Big Pharma, Women’s Health, Cell & Gene Therapy, Corporate VC, CNS Diseases, Medtech Strategics, and Digital Health. At this RESI, we will be featuring two new panel topics, Women’s Health and CNS Diseases. Join our seasoned panelists from a wide range of sectors to get the latest insight on trends, emerging topics, advice, and more!

Take a look below for our panelists who will be giving you the latest scoop:

Elizabeth Bailey Managing Director RH Capital	Caleb Bell Venture Partner Corundum Systems Biology	Nat Brinn Partner VC23
Frederic Cedrone Vice President, Corporate Innovation Catalent Strategic Ventures	Geoff Dacosta Director, Business Development and Licensing Philips Healthcare	Neel Desai Business Development & Licensing Biogen
Marissa Fayer U.S. Partner Goddess Gaia Ventures	Tom Gibbs Director Debiopharm Innovation Fund	Lucio Iannone VP of Investments Leaps by Bayer
Jotthe Kannappan Associate Intuitive Surgical	Arianne Kidder Principal Seae Ventures	Joan Koerber-Walker Co-Founder and Managing Member AZBio
Adam Kundzewicz Executive Director Boehringer Ingelheim Venture Fund	Linda Li Venture Partner Cleveland Clinic Ventures	Wasim Malik Co-Founder and Managing Partner Iaso Ventures
Amanda Mason Director, Global Head of Inflammation Search & Evaluation, Business Development Amgen	John Pennett Angel Investor Mid Atlantic Bio Angels	Jane Rho Investor, Venture Fund DaVita Venture Group
Ronak Savla Director, Strategic Ventures Catalent Strategic Ventures	Yaniv Sneor Founding Member Mid Atlantic Bio Angels	Ashim Subedee Director, Catalyst Office Division of Research Innovation and Ventures (DRIVe)
David Uffer Vice President, MedTech General Inception	Matt Weinberg Partner Max Ventures	Sonia Weiss Co-Founder & Managing Partner WPSS.bio
Andrew Wong Global Head of Bayer CoLabs Bayer	Lu Zhang Managing Partner Fusion Fund